
CapDecisif et al. in €3.6m round for InnaVirVax
A consortium of existing backers, including CapDecisif Management and Fa Dièse, have injected a further €3.6m into HIV-focused French biopharma InnaVirVax.
The company's investors that took part in this latest round include CapDecisif (investing via its FCPR CapDecisif 2 vehicle), seed fund G1J Ile-de-France, family fund Pradeyrol Development, Fa Dièse and FRCI (Fonds Régional de Co-Investissement d'Ile-de-France).
InnaVirVax is now aiming to accelerate the development of its VAC-3S product, which is currently in phase-two clinical trials and is designed to restore the immune system of people living with HIV.
Company
Founded in 2008, InnaVirVax develops therapeutic solutions for infectious diseases and major chronic diseases. It is currently focusing on HIV treatment with its VAC-3S product.
People
Catherine Boule led the deal for CapDecisif.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater